The Serum Institute of India has begun manufacturing New York-based Codagenix’s COVID-19 vaccine candidate CDX-005.

Delivered through the nose, CDX-005 uses a weakened form of the SARS-CoV-2 virus to generate a protective immune response.

The institute will manufacture the vaccine for large-scale safety and efficacy studies, and it will prepare to scale up production to meet global demand if the candidate proves successful.

Codagenix expects to begin phase 1 testing of the vaccine in the UK before the end of this year.